Ligand id: 7384

Name: blinatumomab

No information available.
Summary of Clinical Use
In December 2014 the FDA approved blinatumomab for use in the treatment of Philadelphia chromosome-negative (Ph-) precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL. Blinatumomab is undergoing clinical trial for other forms of ALL and lymphoma. A list of current trials can be viewed at In the European Union blinatumomab may be used under orphan designation for the treatment of ALL.
In July 2017, the FDA expanded approval to include treatment of relapsed or refractory B-cell precursor ALL in adults and children, based on data from the Phase 3 TOWER study that shows that blinatumomab single agent therapy exhibits superior improvement in median overall survival over standard of care chemotherapy. This is the first single-agent immunotherapy approved to treat patients with Ph- relapsed or refractory B-cell precursor ALL.
Mechanism Of Action and Pharmacodynamic Effects
Structurally, blinatumomab carries peptide sequences which interact with CD3e (part of the T cell receptor, TCR, of T cells) and CD19 found on B cells. Functionally, the antibody binds epitopes on T and B cells bringing them together, activating the T cells and directing their cytotoxic effects towards malignant B cells [4].